Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: a pooled phase 1/2/3 randomized clinical study
Nhan Thi Ho, Igor Smolenov, Lydia Tran, Van Thu Nguyen et autres
BACKGROUND: Public health concerns due to ongoing emergence of SARS-CoV-2 variants necessitates further development of improved COVID-19 vaccines. One major innovation are self-amplifying mRNA vaccines, such as ARCT-154 (Arcturus Therapeutics, Inc.), which induces superior immunogenicity compared with conventional mRNA in terms of …
vn, us, fr (code pays fourni par la source)
13 citations
Expert Review of Vaccines